Patent US5693607A successfully refreshed from Google Patents.
US5693607A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Uses of TGF-β receptor fragment as a therapeutic agent
Assignee: Individual
•
Filing: 1994-12-22
•
Granted: 1997-12-02
•
Expires: 2014-12-22
Abstract
Abstract A method of treating TGF-β excess is disclosed. The treatment is parenteral, oral or topical administration of TGF-β receptor fragment. Particularly effective is a soluble receptor fragment which resembles the extracellular portion of TGF-β binding protein II.
Inventors
- 👤 Patricia R. Segarini
- 👤 James R. Dasch
- 👤 David R. Olsen
- 👤 Pedro A. Carrillo
- 👤 Desmond Mascarenhas
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 13:20
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/705; C07K14/71; A; A61; A61P; A61P1/00; A61P1/16; A61P11/00; A61P13/00; A61P13/02; A61P15/00; A61P17/00; A61P27/00; A61P27/02; A61P29/00; A61P3/00; A61P3/08; A61P31/00; A61P31/12; A61P35/00; A61P37/00; A61P37/02; A61K; A61K38/00; C07K2319/00
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
56 words
A method for treating an individual for a medical condition associated with TGF-β excess comprising the step of administering to the individual a high affinity type II TGF-β-binding receptor fragment having the sequence shown as amino acids 1-105 of SEQ ID NO: 2 in an amount sufficient to reduce the activity of TGF-β in said individual.
Claim 2
Independent Claim
56 words
A method for treating an individual for a medical condition associated with TGF-β excess comprising the step of administering to the individual a high affinity type II TGF-β-binding receptor fragment having the sequence shown as amino acids 1-105 of SEQ ID NO: 2 in an amount sufficient to reduce the activity of TGF-β in said individual.
Claim 3
Dependent Claim
28 words
The method of claim 1 wherein the TGF-β receptor fragment is administered by a method selected from the group consisting of intravenous, intraocular, intraarticular, transdermal, and enteral administration.
Claim 4
Dependent Claim
13 words
The method of claim 1 wherein said medical condition comprises a fibroproliferative disorder.
Claim 5
Dependent Claim
24 words
The method of claim 3 wherein said fibroproliferative disorder comprises a fibrosis selected from the group consisting of hepatic, kidney, intraocular, and pulmonary fibrosis.
Claim 6
Dependent Claim
27 words
The method of claim 3 wherein said fibroproliferative disorder is selected from the group consisting of diabetic nephropathy, glomerulonephritis, proliferative vitreoretinopathy, liver cirrhosis, biliary fibrosis, and myelofibrosis.
References Cited (Backward Citations)
US4886747A
Cited
WO1988002406A2
Cited
US5084384A
Cited
WO1989012678A1
Cited
EP0369861A2
Cited
EP0413440A2
Cited
WO1991019513A1
Cited
US5187151A
Cited
WO1992017206A1
Cited
WO1993009228A1
Cited
WO1993010215A1
Cited
WO1993017708A1
Cited
WO1994018991A1
Cited
EP0637450A2
Cited
WO1995010610A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-12-01 | 2001-06-02 | 2001-12-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-12-01 | 2005-06-02 | 2005-12-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-12-01 | 2009-06-02 | 2009-12-02 | $7700.00 | Window Closed / Lapsed |